Custom Adenovirus, Adeno-Associated Virus (AAV), Lentivirus at your fingertips within a matter of weeks, highest titers, at quantities required for preclinical testing, expressed in human expression system, shortly in GMP quality. Novel adenovirus serotype / Ad19a. Contact us in New Hampshire, Tokyo, Munich.
Location: Germany, Bavaria, Martinsried
Employees: 51-200
Phone: +49 89 700961999
Founded date: 2005
Investors 1
| Date | Name | Website |
| - | Creathor V... | creathor.c... |
Mentions in press and media 15
| Date | Title | Description |
| 10.08.2021 | Bringing immuno-oncology cell therapies to the masses – are we (nearly) there yet? | |
| 11.03.2021 | SIRION Biotech Hosts “Engineering AAV Lead Vectors for Gene Therapy” Webinar on March 16 at 9 a.m. EST/3 p.m. CET | SIRION Biotech “As a leader in viral vector-based gene delivery technologies, we look forward to sharing our knowledge via gap analysis case studies showing how undersized rAAV vectors affect the level of process-related impurities such as ... |
| 23.02.2021 | SIRION Biotech Announces Collaboration with Sanofi to Innovate Gene Therapy Treatments with Improved Adeno-Associated Virus Capsids | MUNICH--(BUSINESS WIRE)--Feb 23, 2021-- SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a gl... |
| 23.02.2021 | SIRION Biotech Announces Collaboration with Sanofi to Innovate Gene Therapy Treatments with Improved Adeno-Associated Virus Capsids | Joining forces to develop gene therapies for multiple life-threatening disorders MUNICH–(BUSINESS WIRE)–February 23, 2021– SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, ann... |
| 23.02.2021 | Sanofi partners with SIRION | SIRION Biotech has signed a licensing and collaboration agreement with Sanofi. Together, the two companies aim to develop improved AAV capsids for gene therapy treatments of life-threatening diseases. SIRION Biotech, based in Martinsried n... |
| 04.02.2020 | SIRION Biotech Licenses Adenovirus Technology to Danish Startup, InProTher for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV) | Five years of collaborative discovery work comes to fruition MUNICH & COPENHAGEN, Denmark–(BUSINESS WIRE)–February 4, 2020– SIRION Biotech GmbH (“SIRION”), a world leader in viral vector-based gene delivery technologies for gene and cel... |
| 18.02.2014 | Horizon Discovery signs supply and distribution agreement with Sirion Biotech GmbH | Horizon Discovery signs supply and distribution agreement with Sirion Biotech GmbH 18-02-2014 Horizon Discovery™, a leading provider of research tools to support translational genomics and the development of personalized medicines, announce... |
| 15.04.2013 | Sirion Biotech Closes New Financing | Sirion Biotech GmbH, a Munich, Germany-based specializes in viral vector platforms and provides sophisticated cell modeling, closed a financing round of undisclosed amount. Backers included new investors Aumenta GmbH and an undisclosed anot... |
| - | SIRION Biotech announces collaboration with Sanofi to innovate gene therapy treatments with improved adeno-associated virus capsids | MUNICH, Germany, February 23, 2021—SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global ... |
| - | SIRION Biotech and Denali Therapeutics Join Forces | MUNICH - SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Denali Therapeutics, a biopharmaceutical co... |
Show more